Ardian, a private investment house, completed the acquisition of a minority stake in H2 Pharma, a manufacturer and distributor of generic pharmaceuticals. Financial terms were not disclosed. "The resilience and engagement of H2 Pharma’s management team have steered the company exceptionally well over the past years and we are looking forward to helping them achieve their vision for this next stage of development. Undoubtedly, the company’s competitiveness also comes from its cutting-edge technology, which places it head and shoulders above many of its peers. We see significant potential for strong organic growth and we look forward to helping management realize this by working closely with Henry and his teams," Frédéric Quéru, Ardian Director.